Publications by authors named "Y-L Goh"
Background: In Asia, diabetes-associated death due to cardiorenal diseases were 2-3 times higher in women than men which might be due to gender disparity in quality of care and health habits.
Methods: Adults with type 2 diabetes (T2D) from 11 Asian countries/areas were assessed using the same protocol (2007-2015). We compared treatment target attainment (HbA < 7%, blood pressure [BP] < 130/80 mmHg, risk-based LDL-cholesterol, lack of central obesity [waist circumference <90 cm in men or <80 cm in women), use of cardiorenal-protective drugs (renin-angiotensin system [RAS] inhibitors, statins), and self-reported health habits including self-monitoring blood glucose (SMBG) by gender.
Article Synopsis
- - Rivaroxaban is a medication used to prevent strokes in patients with nonvalvular atrial fibrillation, and its clearance mainly involves enzymes CYP3A4, CYP2J2, and P-glycoprotein (P-gp).
- - Antiarrhythmic drugs like amiodarone and dronedarone, while managing atrial fibrillation, can inhibit these enzymes, potentially increasing rivaroxaban levels in the body by reducing its clearance.
- - In vitro studies showed that dronedarone and its metabolite affected rivaroxaban metabolism more significantly than amiodarone, predicting an increase in rivaroxaban exposure by 37% and 31%, with additional
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development.
View Article and Find Full Text PDFPurpose: To determine if first-order and high-order textural features on fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) images of non-small cell lung cancer (NSCLC) (a) at baseline, (b) at 6 weeks, or (c) the percentage change between baseline and 6 weeks can predict response or survival in patients treated with erlotinib.
Materials And Methods: Institutional review board approval was obtained for post hoc analysis of data from a prospective single-center study for which informed consent was obtained. The study included 47 patients with NSCLC who underwent (18)F-FDG PET/computed tomography (CT) at baseline (n = 47) and 6 weeks (n = 40) after commencing treatment with erlotinib.